KAI-4729

updated

KAI-4729 (HRS-4729 at Hengrui) is an investigational once-weekly injectable GLP-1, GIP and glucagon receptor triple agonist, with Kailera holding rights outside Greater China. Its only human data are two company statements (26 May and 1 October 2026) from a 12-week multiple-dose phase 1 cohort: up to 16.0% weight loss at 12 mg versus 5.4% on placebo, while a GLP-1/GIP dual agonist control lost 16.7%, with 10 participants per arm. Nothing is peer reviewed or posted in a registry, and sharing receptors with retatrutide is not evidence for KAI-4729.

GLP-1, GIP and glucagon receptor triple agonist

  • Kailera's pipeline page lists KAI-4729 as a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist in clinical development for obesity, and Kailera's releases give Hengrui's code as HRS-4729.
  • PubChem has no record for KAI-4729 or HRS-4729, so no formula, molecular weight, CAS number or sequence is available.
  • The company reported on 26 May 2026 that in a 12-week multiple-dose cohort of 60 participants, the 12 mg group lost up to 16.0% from baseline versus 5.4% on placebo, with a half-life of about 4 to 5 days. This is not peer reviewed.
  • On 1 October 2026 the company reported that the 12 mg group (N=10) lost up to 16.0% and the 4 mg ribupatide control group (N=10), a GLP-1/GIP dual agonist, lost 16.7%, with no statistical comparison reported.
  • The first-in-human trial NCT06762600 (102 enrolled) and three phase 2 studies in China are registered, and none has posted results. PubMed searches on 10 October 2026 returned 0 records for KAI-4729 or HRS-4729.
  • Retatrutide acts on the same three receptors and has phase 3 data (TRIUMPH-1, 2339 adults), but those data belong to retatrutide and say nothing about KAI-4729.

What is KAI-4729, and is it approved anywhere?

KAI-4729 (HRS-4729 at Hengrui) is a once-weekly injectable GLP-1, GIP and glucagon receptor triple agonist in clinical development for obesity, with Kailera holding rights outside Greater China. No approval or marketing application appears in any source reviewed, and PubChem has no record, so no formula, molecular weight or sequence is available.

Kailera's pipeline page, read on 10 October 2026, lists KAI-4729 as a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist in clinical development for obesity. Kailera's releases of 26 May 2026 and 1 October 2026 give Hengrui's code for the same molecule as HRS-4729 (KAI-4729). The releases say Hengrui granted Kailera exclusive rights outside Greater China to its GLP-1 portfolio in May 2024 and name KAI-4729 as a Kailera program. The license terms specific to KAI-4729 were not located.

The first-in-human trial was run by Hengrui in China and is registered by Fujian Shengdi Pharmaceutical Co., Ltd. (NCT06762600), and the registry does not state that company's relation to Hengrui. It is a randomized, double-blind, placebo-controlled phase 1 study of single and multiple subcutaneous doses in healthy participants aged 18 to 55, with 102 enrolled and primary completion on 12 March 2026.

PubChem has no record for KAI-4729 or HRS-4729, so no formula, molecular weight, CAS number or sequence is available from an official chemical record, and no INN was found. No approval or marketing application for KAI-4729 appears in any source reviewed.

Company pipeline page, 10 October 2026: KAI-4729, code HRS-4729, rights outside Greater China

Regulatory record

Kailera Therapeutics development pipeline page, read on 10 October 2026, with Kailera releases of 26 May 2026 and 1 October 2026; registry NCT06762600. PubChem searches run the same day.

Kailera's pipeline page lists KAI-4729 as a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist in clinical development for obesity. Kailera's releases of 2026-05-26 and 2026-10-01 give Hengrui's code for the same molecule as HRS-4729 (KAI-4729). The first-in-human trial was run by Hengrui in China and is registered by Fujian Shengdi Pharmaceutical Co., Ltd. (NCT06762600); the registry does not state that company's relation to Hengrui. The releases say Hengrui granted Kailera exclusive rights outside Greater China to its GLP-1 portfolio in May 2024 and name KAI-4729 as a Kailera program; the license terms specific to KAI-4729 were not located. PubChem has no record for KAI-4729 or HRS-4729, so no formula, molecular weight or sequence is available from an official chemical record.

Participants / model
Chemical identity, not a clinical population
Treatment
Once-weekly subcutaneous injection
Follow-up
Not applicable
Study design
Company pipeline page and releases, with PubChem name searches; not peer reviewed
Funding
not stated in the source

The code mapping rests on Kailera's own statements.

Read the original source
Registry: first-in-human phase 1, 102 enrolled, no posted results

Trial registry record

ClinicalTrials.gov record NCT06762600, read on 10 October 2026.

NCT06762600 is a randomized, double-blind, placebo-controlled phase 1 study of single and multiple subcutaneous doses of HRS-4729 injection in healthy participants aged 18 to 55 (enrollment 102 actual; start 2025-01-16; primary completion 2026-03-12; interventions include HRS-4729, HRS9531 and acetaminophen). A registration without results is not an outcome, and this record has no posted results.

Participants / model
Healthy participants aged 18 to 55
Treatment
HRS-4729 injection, subcutaneous, versus placebo
Follow-up
Start 16 January 2025; primary completion 12 March 2026
Study design
Trial registry record; no posted results
Funding
not stated in the source

The registry sponsor is Fujian Shengdi Pharmaceutical Co., Ltd., and the registry does not state that company's relation to Hengrui.

Read the original source

What human data exist for KAI-4729, and where do they come from?

Only two company statements, dated 26 May and 1 October 2026. In a 12-week multiple-dose phase 1 cohort of 60 participants, the 12 mg group lost up to 16.0% of body weight versus 5.4% on placebo, while a 4 mg GLP-1/GIP dual agonist control lost 16.7%, with 10 participants per arm. Neither is peer reviewed, and the registry has no posted results.

On 26 May 2026 Kailera reported topline data from Hengrui's phase 1 SAD/MAD trial (NCT06762600). The multiple-dose portion enrolled 60 participants (mean baseline weight 87.3 kg, BMI 31.4 kg/m2) who received once-weekly 1, 4, 8 or 12 mg HRS-4729, 4 mg ribupatide as an active control, or placebo for 12 weeks. At week 12 the 12 mg group achieved a mean weight loss of up to 16.0% from baseline versus 5.4% on placebo. The release reports linear pharmacokinetics with a half-life of about 4 to 5 days, mostly mild to moderate gastrointestinal adverse events, and a dose-dependent fall in liver fat by MRI-PDFF.

On 1 October 2026 Kailera reported more detail from the multiple-dose portion at week 12. The 12 mg group (N=10) achieved a mean weight loss of up to 16.0% and a 67.3% mean reduction in liver fat content. The 4 mg ribupatide control group (N=10) had a mean body weight reduction of 16.7% and a 38.4% mean liver fat reduction. The GLP-1/GIP dual agonist control therefore lost numerically more weight (16.7%) than the tri-agonist's top dose (16.0%) in this trial. No statistical comparison between arms is reported, and the two arms had 10 participants each. BMI ranged 28 to 40 kg/m2 in this portion.

The 16.0% is described as up to 16.0% in the releases. A PubMed search on 10 October 2026 for KAI-4729 or HRS-4729 returned 0 records, and the registry record has no posted results, so there is no peer-reviewed or registry-posted human data for this compound. The full phase 1 dataset and confidence intervals were not available.

Company statement, 26 May 2026: phase 1 MAD topline, up to 16.0% at 12 weeks, not peer reviewed

Regulatory record

Kailera Therapeutics first-quarter 2026 results press release, 26 May 2026.

The company reported topline data from Hengrui's phase 1 SAD/MAD trial (NCT06762600). The MAD portion enrolled 60 participants (mean baseline weight 87.3 kg, BMI 31.4 kg/m2) who received once-weekly 1, 4, 8 or 12 mg HRS-4729, 4 mg ribupatide as active control, or placebo for 12 weeks. The release reports linear pharmacokinetics with a half-life of about 4 to 5 days, and at week 12 the 12 mg group achieved a mean weight loss of up to 16.0% from baseline versus 5.4% on placebo. Most treatment-emergent adverse events were mild to moderate and gastrointestinal, and liver fat fell in a dose-dependent way by MRI-PDFF.

Participants / model
Healthy participants in a 12-week multiple-ascending-dose cohort (60 participants; mean baseline weight 87.3 kg, BMI 31.4 kg/m2)
Treatment
HRS-4729 1, 4, 8 or 12 mg subcutaneously once weekly, 4 mg ribupatide as active control, or placebo
Follow-up
12 weeks
Study design
Company earnings release on a phase 1 multiple-ascending-dose cohort; not peer reviewed
Funding
not stated in the source

Not peer reviewed.

Read the original source
Company statement, 1 October 2026: 12 mg versus a dual-agonist control, 10 participants per arm

Regulatory record

Kailera Therapeutics press release, 1 October 2026, on GlobeNewswire.

In the MAD portion at week 12, the 12 mg group (N=10) achieved a mean weight loss of up to 16.0% and a 67.3% mean reduction in liver fat content, and the 4 mg ribupatide control group (N=10) had a mean body weight reduction of 16.7% and a 38.4% mean liver fat reduction. The GLP-1/GIP dual agonist control therefore lost numerically more weight (16.7%) than the tri-agonist's top dose (16.0%) in this trial; no statistical comparison between arms is reported and the two arms had 10 participants each. BMI ranged 28 to 40 kg/m2 in the MAD portion.

Participants / model
10 participants in each of the two arms named, in the MAD portion (BMI 28 to 40 kg/m2)
Treatment
HRS-4729 12 mg or ribupatide 4 mg subcutaneously once weekly
Follow-up
12 weeks
Study design
Company press release on a meeting presentation; not peer reviewed
Funding
not stated in the source

The 16.0% is described as up to 16.0% in the release, and each arm had 10 participants. The full phase 1 dataset and confidence intervals were not available, and the meeting abstract is cited only through this release.

Read the original source
Searches, 10 October 2026: 0 PubMed records, 5 registry records, no posted results

PubMed search record

PubMed searches for KAI-4729, HRS-4729 and HRS-4729 OR HRS4729, and ClinicalTrials.gov queries for KAI-4729 and HRS-4729, run on 10 October 2026.

PubMed searches for KAI-4729 and for HRS-4729 each returned 0 records, and a search for HRS-4729 OR HRS4729 also returned 0. A ClinicalTrials.gov query for KAI-4729 returned 0 records and one for HRS-4729 returned 5 (2 phase 1, 3 phase 2), none with posted results. No Kailera-registered trial of KAI-4729 was found. In the records reviewed there is no peer-reviewed or registry-posted human data for this compound; the only human data are the two company statements.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Searches run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

A search result shows what the databases returned on that date. It is not proof that no unindexed report exists.

Read the original source

Which studies are registered, and do they have results?

Three phase 2 studies in China are registered, in obesity, MASH and type 2 diabetes, and none has results. The first-in-human phase 1 is registered with 102 enrolled and no posted results. Kailera says it plans a phase 1 trial outside China in 2026 with data expected in 2027.

A ClinicalTrials.gov query for HRS-4729 on 10 October 2026 returned 5 records (2 phase 1, 3 phase 2), none with posted results. The phase 2 studies are NCT07690826 (obesity, estimated 252 participants, not yet recruiting, registry start July 2026, primary outcome percent change in body weight at week 32), NCT07660848 (a MASH master protocol with HRS9531, estimated 160, recruiting, start 14 August 2026) and NCT07843862 (type 2 diabetes versus mazdutide and placebo, estimated 240, not yet recruiting, start October 2026). All three are sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. in China.

These are registrations, and none has results. Kailera says it plans a phase 1 trial outside China in 2026 with data expected in 2027, and that trial had no registry record on 10 October 2026. No Kailera-registered trial of KAI-4729 was found.

Registry: three phase 2 studies in China, none with results; Kailera plans a phase 1 outside China

Trial registry record

ClinicalTrials.gov records NCT07690826, NCT07660848 and NCT07843862, read on 10 October 2026; Kailera statements on a phase 1 trial outside China.

Phase 2 studies are registered and none has results. NCT07690826 (obesity, estimated n=252, not yet recruiting, registry start 2026-07, primary outcome percent change in body weight at week 32), NCT07660848 (MASH master protocol with HRS9531, estimated n=160, recruiting, start 2026-08-14) and NCT07843862 (type 2 diabetes versus mazdutide and placebo, estimated n=240, not yet recruiting, start 2026-10) are all sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. in China. These are registrations; none has results. Kailera says it plans a phase 1 trial outside China in 2026 with data expected in 2027.

Participants / model
Registered participants, not a clinical population
Treatment
HRS-4729 injection, once weekly
Follow-up
Registry start dates from July to October 2026
Study design
Trial registry records and a company statement; no results
Funding
not stated in the source

A registration describes a plan, not a result. Kailera's non-China phase 1 had no registry record on 10 October 2026.

Read the original source
Registry: first-in-human phase 1, 102 enrolled, no posted results

Trial registry record

ClinicalTrials.gov record NCT06762600, read on 10 October 2026.

NCT06762600 is a randomized, double-blind, placebo-controlled phase 1 study of single and multiple subcutaneous doses of HRS-4729 injection in healthy participants aged 18 to 55 (enrollment 102 actual; start 2025-01-16; primary completion 2026-03-12; interventions include HRS-4729, HRS9531 and acetaminophen). A registration without results is not an outcome, and this record has no posted results.

Participants / model
Healthy participants aged 18 to 55
Treatment
HRS-4729 injection, subcutaneous, versus placebo
Follow-up
Start 16 January 2025; primary completion 12 March 2026
Study design
Trial registry record; no posted results
Funding
not stated in the source

The registry sponsor is Fujian Shengdi Pharmaceutical Co., Ltd., and the registry does not state that company's relation to Hengrui.

Read the original source
Searches, 10 October 2026: 0 PubMed records, 5 registry records, no posted results

PubMed search record

PubMed searches for KAI-4729, HRS-4729 and HRS-4729 OR HRS4729, and ClinicalTrials.gov queries for KAI-4729 and HRS-4729, run on 10 October 2026.

PubMed searches for KAI-4729 and for HRS-4729 each returned 0 records, and a search for HRS-4729 OR HRS4729 also returned 0. A ClinicalTrials.gov query for KAI-4729 returned 0 records and one for HRS-4729 returned 5 (2 phase 1, 3 phase 2), none with posted results. No Kailera-registered trial of KAI-4729 was found. In the records reviewed there is no peer-reviewed or registry-posted human data for this compound; the only human data are the two company statements.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Searches run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

A search result shows what the databases returned on that date. It is not proof that no unindexed report exists.

Read the original source

Do retatrutide's phase 3 results apply to KAI-4729?

No. Retatrutide is a different molecule that acts on the same three receptors. In TRIUMPH-1 (2339 adults without diabetes) it gave -17.6% to -25.0% weight change at 80 weeks versus -3.9% on placebo, but that is not evidence of the potency, efficacy or safety of KAI-4729.

Retatrutide is a triple agonist of the GIP, GLP-1 and glucagon receptors. In the phase 3 TRIUMPH-1 trial in 2339 adults with obesity without diabetes, mean body weight change at 80 weeks was -17.6% (4 mg), -23.7% (9 mg) and -25.0% (12 mg) versus -3.9% on placebo, and the most common adverse events were gastrointestinal. This shows the receptor combination has phase 3 data for retatrutide.

It is not evidence of the potency, efficacy or safety of KAI-4729, whose human data are limited to the company statements above. In the retatrutide phase 2 trial in 338 adults with obesity, gastrointestinal events were dose-related and dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. A heart-rate effect is a class question for glucagon-receptor agonists, and it was not reported for KAI-4729 in the sources reviewed.

Different molecule: retatrutide phase 3, 2339 adults, 80 weeks, -17.6% to -25.0%

Randomized controlled trial

Jastreboff AM et al. N Engl J Med. 2026. PMID 42814954.

Retatrutide is a triple agonist of the GIP, GLP-1 and glucagon receptors. In the phase 3 TRIUMPH-1 trial in 2339 adults with obesity without diabetes, mean body weight change at 80 weeks was -17.6% (4 mg), -23.7% (9 mg) and -25.0% (12 mg) versus -3.9% on placebo; the most common adverse events were gastrointestinal. This shows the receptor combination has phase 3 data for retatrutide. It is not evidence of the potency, efficacy or safety of KAI-4729, whose human data are limited to the company statements.

Participants / model
2339 adults with obesity without diabetes (retatrutide, not KAI-4729)
Treatment
Retatrutide 4, 9 or 12 mg subcutaneously once weekly, or placebo
Follow-up
80 weeks
Study design
Randomized phase 3 trial of a different molecule, used here as class context
Funding
not stated in the source

A different molecule. It is cited only to show the receptor combination has phase 3 data for retatrutide.

Read the original source
Different molecule: retatrutide phase 2, 338 adults, 48 weeks, heart rate and gastrointestinal events

Randomized controlled trial

Jastreboff AM et al. N Engl J Med. 2023;389(6):514-526. PMID 37366315.

In the retatrutide phase 2 trial in 338 adults with obesity, the gastrointestinal events were dose-related, and the abstract states that dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. A heart-rate effect is a class question for glucagon-receptor agonists; it was not reported for KAI-4729 in the sources reviewed.

Participants / model
338 adults with obesity (retatrutide, not KAI-4729)
Treatment
Retatrutide 1 to 12 mg subcutaneously once weekly
Follow-up
48 weeks
Study design
Randomized phase 2 trial of a different molecule, used here as class context
Funding
not stated in the source

A different molecule. Heart rate is a class question for glucagon-receptor agonists, not a finding for KAI-4729.

Read the original source

Is KAI-4729 a phase 1 triple agonist licensed from Hengrui that acts on the same receptors as retatrutide?

The description is supported by Kailera's own pipeline page and releases: a GLP-1, GIP and glucagon triple agonist, with human data from phase 1 and rights licensed from Hengrui. The same-receptors statement is true as a description of mechanism only.

Sellers describe KAI-4729 as a GLP-1, GIP and glucagon receptor triple agonist licensed by Kailera from Hengrui, in phase 1, acting on the same three receptors as retatrutide.

Kailera's pipeline page and releases support the description, and give Hengrui's code as HRS-4729. The human data come from a phase 1 trial, and three phase 2 studies are registered in China with no results. The statement about retatrutide is true as a description of mechanism: both compounds are described as acting on the GLP-1, GIP and glucagon receptors. It does not carry any efficacy or safety claim, because retatrutide's phase 3 data belong to retatrutide.

Company pipeline page, 10 October 2026: KAI-4729, code HRS-4729, rights outside Greater China

Regulatory record

Kailera Therapeutics development pipeline page, read on 10 October 2026, with Kailera releases of 26 May 2026 and 1 October 2026; registry NCT06762600. PubChem searches run the same day.

Kailera's pipeline page lists KAI-4729 as a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist in clinical development for obesity. Kailera's releases of 2026-05-26 and 2026-10-01 give Hengrui's code for the same molecule as HRS-4729 (KAI-4729). The first-in-human trial was run by Hengrui in China and is registered by Fujian Shengdi Pharmaceutical Co., Ltd. (NCT06762600); the registry does not state that company's relation to Hengrui. The releases say Hengrui granted Kailera exclusive rights outside Greater China to its GLP-1 portfolio in May 2024 and name KAI-4729 as a Kailera program; the license terms specific to KAI-4729 were not located. PubChem has no record for KAI-4729 or HRS-4729, so no formula, molecular weight or sequence is available from an official chemical record.

Participants / model
Chemical identity, not a clinical population
Treatment
Once-weekly subcutaneous injection
Follow-up
Not applicable
Study design
Company pipeline page and releases, with PubChem name searches; not peer reviewed
Funding
not stated in the source

The code mapping rests on Kailera's own statements.

Read the original source
Company statement, 26 May 2026: phase 1 MAD topline, up to 16.0% at 12 weeks, not peer reviewed

Regulatory record

Kailera Therapeutics first-quarter 2026 results press release, 26 May 2026.

The company reported topline data from Hengrui's phase 1 SAD/MAD trial (NCT06762600). The MAD portion enrolled 60 participants (mean baseline weight 87.3 kg, BMI 31.4 kg/m2) who received once-weekly 1, 4, 8 or 12 mg HRS-4729, 4 mg ribupatide as active control, or placebo for 12 weeks. The release reports linear pharmacokinetics with a half-life of about 4 to 5 days, and at week 12 the 12 mg group achieved a mean weight loss of up to 16.0% from baseline versus 5.4% on placebo. Most treatment-emergent adverse events were mild to moderate and gastrointestinal, and liver fat fell in a dose-dependent way by MRI-PDFF.

Participants / model
Healthy participants in a 12-week multiple-ascending-dose cohort (60 participants; mean baseline weight 87.3 kg, BMI 31.4 kg/m2)
Treatment
HRS-4729 1, 4, 8 or 12 mg subcutaneously once weekly, 4 mg ribupatide as active control, or placebo
Follow-up
12 weeks
Study design
Company earnings release on a phase 1 multiple-ascending-dose cohort; not peer reviewed
Funding
not stated in the source

Not peer reviewed.

Read the original source
Different molecule: retatrutide phase 3, 2339 adults, 80 weeks, -17.6% to -25.0%

Randomized controlled trial

Jastreboff AM et al. N Engl J Med. 2026. PMID 42814954.

Retatrutide is a triple agonist of the GIP, GLP-1 and glucagon receptors. In the phase 3 TRIUMPH-1 trial in 2339 adults with obesity without diabetes, mean body weight change at 80 weeks was -17.6% (4 mg), -23.7% (9 mg) and -25.0% (12 mg) versus -3.9% on placebo; the most common adverse events were gastrointestinal. This shows the receptor combination has phase 3 data for retatrutide. It is not evidence of the potency, efficacy or safety of KAI-4729, whose human data are limited to the company statements.

Participants / model
2339 adults with obesity without diabetes (retatrutide, not KAI-4729)
Treatment
Retatrutide 4, 9 or 12 mg subcutaneously once weekly, or placebo
Follow-up
80 weeks
Study design
Randomized phase 3 trial of a different molecule, used here as class context
Funding
not stated in the source

A different molecule. It is cited only to show the receptor combination has phase 3 data for retatrutide.

Read the original source

How does KAI-4729 work, and how long does it stay in the body?

Kailera describes it as a once-weekly injectable GLP-1, GIP and glucagon receptor tri-agonist. The company reported on 26 May 2026 linear pharmacokinetics with a half-life of about 4 to 5 days in a 12-week multiple-dose cohort. No receptor pharmacology or animal data appear in the sources reviewed.

The only description of the mechanism is the company's: a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist in clinical development for obesity. The sources reviewed contain no receptor pharmacology, animal data or sequence.

The 26 May 2026 company statement reports linear pharmacokinetics with a half-life of about 4 to 5 days in the 12-week multiple-dose cohort of 60 participants, and a dose-dependent fall in liver fat by MRI-PDFF. These are company statements without numbers beyond the stated half-life range, and they are not peer reviewed.

Company pipeline page, 10 October 2026: KAI-4729, code HRS-4729, rights outside Greater China

Regulatory record

Kailera Therapeutics development pipeline page, read on 10 October 2026, with Kailera releases of 26 May 2026 and 1 October 2026; registry NCT06762600. PubChem searches run the same day.

Kailera's pipeline page lists KAI-4729 as a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist in clinical development for obesity. Kailera's releases of 2026-05-26 and 2026-10-01 give Hengrui's code for the same molecule as HRS-4729 (KAI-4729). The first-in-human trial was run by Hengrui in China and is registered by Fujian Shengdi Pharmaceutical Co., Ltd. (NCT06762600); the registry does not state that company's relation to Hengrui. The releases say Hengrui granted Kailera exclusive rights outside Greater China to its GLP-1 portfolio in May 2024 and name KAI-4729 as a Kailera program; the license terms specific to KAI-4729 were not located. PubChem has no record for KAI-4729 or HRS-4729, so no formula, molecular weight or sequence is available from an official chemical record.

Participants / model
Chemical identity, not a clinical population
Treatment
Once-weekly subcutaneous injection
Follow-up
Not applicable
Study design
Company pipeline page and releases, with PubChem name searches; not peer reviewed
Funding
not stated in the source

The code mapping rests on Kailera's own statements.

Read the original source
Company statement, 26 May 2026: phase 1 MAD topline, up to 16.0% at 12 weeks, not peer reviewed

Regulatory record

Kailera Therapeutics first-quarter 2026 results press release, 26 May 2026.

The company reported topline data from Hengrui's phase 1 SAD/MAD trial (NCT06762600). The MAD portion enrolled 60 participants (mean baseline weight 87.3 kg, BMI 31.4 kg/m2) who received once-weekly 1, 4, 8 or 12 mg HRS-4729, 4 mg ribupatide as active control, or placebo for 12 weeks. The release reports linear pharmacokinetics with a half-life of about 4 to 5 days, and at week 12 the 12 mg group achieved a mean weight loss of up to 16.0% from baseline versus 5.4% on placebo. Most treatment-emergent adverse events were mild to moderate and gastrointestinal, and liver fat fell in a dose-dependent way by MRI-PDFF.

Participants / model
Healthy participants in a 12-week multiple-ascending-dose cohort (60 participants; mean baseline weight 87.3 kg, BMI 31.4 kg/m2)
Treatment
HRS-4729 1, 4, 8 or 12 mg subcutaneously once weekly, 4 mg ribupatide as active control, or placebo
Follow-up
12 weeks
Study design
Company earnings release on a phase 1 multiple-ascending-dose cohort; not peer reviewed
Funding
not stated in the source

Not peer reviewed.

Read the original source

What adverse effects have been reported?

Only one statement: on 26 May 2026 the company said most treatment-emergent adverse events in a 60-participant, 12-week cohort were mild to moderate and gastrointestinal. Discontinuations, serious adverse events and heart-rate effects are not reported for KAI-4729. Heart rate is a class question for glucagon-receptor agonists.

In the company statement of 26 May 2026, most treatment-emergent adverse events in the 12-week multiple-dose cohort of 60 participants were mild to moderate and gastrointestinal. Discontinuations, serious adverse events and heart-rate effects are not reported for KAI-4729 in the sources reviewed.

For a different molecule, retatrutide, gastrointestinal events were dose-related in a 338-adult phase 2 trial and dose-dependent heart-rate increases peaked at 24 weeks and declined thereafter. A heart-rate effect is a class question for glucagon-receptor agonists, and it is not reported for KAI-4729.

No peer-reviewed or registry-posted safety data exist for KAI-4729, and no animal toxicity data appear in the sources reviewed.

Company statement, 26 May 2026: phase 1 MAD topline, up to 16.0% at 12 weeks, not peer reviewed

Regulatory record

Kailera Therapeutics first-quarter 2026 results press release, 26 May 2026.

The company reported topline data from Hengrui's phase 1 SAD/MAD trial (NCT06762600). The MAD portion enrolled 60 participants (mean baseline weight 87.3 kg, BMI 31.4 kg/m2) who received once-weekly 1, 4, 8 or 12 mg HRS-4729, 4 mg ribupatide as active control, or placebo for 12 weeks. The release reports linear pharmacokinetics with a half-life of about 4 to 5 days, and at week 12 the 12 mg group achieved a mean weight loss of up to 16.0% from baseline versus 5.4% on placebo. Most treatment-emergent adverse events were mild to moderate and gastrointestinal, and liver fat fell in a dose-dependent way by MRI-PDFF.

Participants / model
Healthy participants in a 12-week multiple-ascending-dose cohort (60 participants; mean baseline weight 87.3 kg, BMI 31.4 kg/m2)
Treatment
HRS-4729 1, 4, 8 or 12 mg subcutaneously once weekly, 4 mg ribupatide as active control, or placebo
Follow-up
12 weeks
Study design
Company earnings release on a phase 1 multiple-ascending-dose cohort; not peer reviewed
Funding
not stated in the source

Not peer reviewed.

Read the original source
Different molecule: retatrutide phase 2, 338 adults, 48 weeks, heart rate and gastrointestinal events

Randomized controlled trial

Jastreboff AM et al. N Engl J Med. 2023;389(6):514-526. PMID 37366315.

In the retatrutide phase 2 trial in 338 adults with obesity, the gastrointestinal events were dose-related, and the abstract states that dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. A heart-rate effect is a class question for glucagon-receptor agonists; it was not reported for KAI-4729 in the sources reviewed.

Participants / model
338 adults with obesity (retatrutide, not KAI-4729)
Treatment
Retatrutide 1 to 12 mg subcutaneously once weekly
Follow-up
48 weeks
Study design
Randomized phase 2 trial of a different molecule, used here as class context
Funding
not stated in the source

A different molecule. Heart rate is a class question for glucagon-receptor agonists, not a finding for KAI-4729.

Read the original source
Searches, 10 October 2026: 0 PubMed records, 5 registry records, no posted results

PubMed search record

PubMed searches for KAI-4729, HRS-4729 and HRS-4729 OR HRS4729, and ClinicalTrials.gov queries for KAI-4729 and HRS-4729, run on 10 October 2026.

PubMed searches for KAI-4729 and for HRS-4729 each returned 0 records, and a search for HRS-4729 OR HRS4729 also returned 0. A ClinicalTrials.gov query for KAI-4729 returned 0 records and one for HRS-4729 returned 5 (2 phase 1, 3 phase 2), none with posted results. No Kailera-registered trial of KAI-4729 was found. In the records reviewed there is no peer-reviewed or registry-posted human data for this compound; the only human data are the two company statements.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Searches run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

A search result shows what the databases returned on that date. It is not proof that no unindexed report exists.

Read the original source

Why does KAI-4729 sit in C tier?

C reflects a compound whose only human data are company statements (26 May and 1 October 2026) from a 60-participant, 12-week study with 10 participants per top-dose arm, in which a dual agonist control lost numerically more weight than the tri-agonist's top dose (16.7% versus 16.0%). The shared receptor combination with retatrutide makes the biology plausible but carries no efficacy or safety claim.

KAI-4729's only human data are company statements (26 May and 1 October 2026) from a 60-participant, 12-week multiple-dose study with 10 participants per top-dose arm. In that study the active comparator, a GLP-1/GIP dual agonist, lost numerically more weight than the tri-agonist's top dose (16.7% versus 16.0%).

The site grades phase 1 compounds C or D and puts retatrutide, which shares the receptor combination and has published phase 3 data, at S. The shared mechanism makes the biology plausible, but a mechanism match carries no efficacy or safety claim, so C rather than D.

Company statement, 26 May 2026: phase 1 MAD topline, up to 16.0% at 12 weeks, not peer reviewed

Regulatory record

Kailera Therapeutics first-quarter 2026 results press release, 26 May 2026.

The company reported topline data from Hengrui's phase 1 SAD/MAD trial (NCT06762600). The MAD portion enrolled 60 participants (mean baseline weight 87.3 kg, BMI 31.4 kg/m2) who received once-weekly 1, 4, 8 or 12 mg HRS-4729, 4 mg ribupatide as active control, or placebo for 12 weeks. The release reports linear pharmacokinetics with a half-life of about 4 to 5 days, and at week 12 the 12 mg group achieved a mean weight loss of up to 16.0% from baseline versus 5.4% on placebo. Most treatment-emergent adverse events were mild to moderate and gastrointestinal, and liver fat fell in a dose-dependent way by MRI-PDFF.

Participants / model
Healthy participants in a 12-week multiple-ascending-dose cohort (60 participants; mean baseline weight 87.3 kg, BMI 31.4 kg/m2)
Treatment
HRS-4729 1, 4, 8 or 12 mg subcutaneously once weekly, 4 mg ribupatide as active control, or placebo
Follow-up
12 weeks
Study design
Company earnings release on a phase 1 multiple-ascending-dose cohort; not peer reviewed
Funding
not stated in the source

Not peer reviewed.

Read the original source
Company statement, 1 October 2026: 12 mg versus a dual-agonist control, 10 participants per arm

Regulatory record

Kailera Therapeutics press release, 1 October 2026, on GlobeNewswire.

In the MAD portion at week 12, the 12 mg group (N=10) achieved a mean weight loss of up to 16.0% and a 67.3% mean reduction in liver fat content, and the 4 mg ribupatide control group (N=10) had a mean body weight reduction of 16.7% and a 38.4% mean liver fat reduction. The GLP-1/GIP dual agonist control therefore lost numerically more weight (16.7%) than the tri-agonist's top dose (16.0%) in this trial; no statistical comparison between arms is reported and the two arms had 10 participants each. BMI ranged 28 to 40 kg/m2 in the MAD portion.

Participants / model
10 participants in each of the two arms named, in the MAD portion (BMI 28 to 40 kg/m2)
Treatment
HRS-4729 12 mg or ribupatide 4 mg subcutaneously once weekly
Follow-up
12 weeks
Study design
Company press release on a meeting presentation; not peer reviewed
Funding
not stated in the source

The 16.0% is described as up to 16.0% in the release, and each arm had 10 participants. The full phase 1 dataset and confidence intervals were not available, and the meeting abstract is cited only through this release.

Read the original source
Different molecule: retatrutide phase 3, 2339 adults, 80 weeks, -17.6% to -25.0%

Randomized controlled trial

Jastreboff AM et al. N Engl J Med. 2026. PMID 42814954.

Retatrutide is a triple agonist of the GIP, GLP-1 and glucagon receptors. In the phase 3 TRIUMPH-1 trial in 2339 adults with obesity without diabetes, mean body weight change at 80 weeks was -17.6% (4 mg), -23.7% (9 mg) and -25.0% (12 mg) versus -3.9% on placebo; the most common adverse events were gastrointestinal. This shows the receptor combination has phase 3 data for retatrutide. It is not evidence of the potency, efficacy or safety of KAI-4729, whose human data are limited to the company statements.

Participants / model
2339 adults with obesity without diabetes (retatrutide, not KAI-4729)
Treatment
Retatrutide 4, 9 or 12 mg subcutaneously once weekly, or placebo
Follow-up
80 weeks
Study design
Randomized phase 3 trial of a different molecule, used here as class context
Funding
not stated in the source

A different molecule. It is cited only to show the receptor combination has phase 3 data for retatrutide.

Read the original source
Searches, 10 October 2026: 0 PubMed records, 5 registry records, no posted results

PubMed search record

PubMed searches for KAI-4729, HRS-4729 and HRS-4729 OR HRS4729, and ClinicalTrials.gov queries for KAI-4729 and HRS-4729, run on 10 October 2026.

PubMed searches for KAI-4729 and for HRS-4729 each returned 0 records, and a search for HRS-4729 OR HRS4729 also returned 0. A ClinicalTrials.gov query for KAI-4729 returned 0 records and one for HRS-4729 returned 5 (2 phase 1, 3 phase 2), none with posted results. No Kailera-registered trial of KAI-4729 was found. In the records reviewed there is no peer-reviewed or registry-posted human data for this compound; the only human data are the two company statements.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Searches run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

A search result shows what the databases returned on that date. It is not proof that no unindexed report exists.

Read the original source

Studies and sources

Company pipeline page, 10 October 2026: KAI-4729, code HRS-4729, rights outside Greater China

Regulatory record

Kailera Therapeutics development pipeline page, read on 10 October 2026, with Kailera releases of 26 May 2026 and 1 October 2026; registry NCT06762600. PubChem searches run the same day.

Kailera's pipeline page lists KAI-4729 as a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist in clinical development for obesity. Kailera's releases of 2026-05-26 and 2026-10-01 give Hengrui's code for the same molecule as HRS-4729 (KAI-4729). The first-in-human trial was run by Hengrui in China and is registered by Fujian Shengdi Pharmaceutical Co., Ltd. (NCT06762600); the registry does not state that company's relation to Hengrui. The releases say Hengrui granted Kailera exclusive rights outside Greater China to its GLP-1 portfolio in May 2024 and name KAI-4729 as a Kailera program; the license terms specific to KAI-4729 were not located. PubChem has no record for KAI-4729 or HRS-4729, so no formula, molecular weight or sequence is available from an official chemical record.

Participants / model
Chemical identity, not a clinical population
Treatment
Once-weekly subcutaneous injection
Follow-up
Not applicable
Study design
Company pipeline page and releases, with PubChem name searches; not peer reviewed
Funding
not stated in the source

The code mapping rests on Kailera's own statements.

Read the original source
Registry: first-in-human phase 1, 102 enrolled, no posted results

Trial registry record

ClinicalTrials.gov record NCT06762600, read on 10 October 2026.

NCT06762600 is a randomized, double-blind, placebo-controlled phase 1 study of single and multiple subcutaneous doses of HRS-4729 injection in healthy participants aged 18 to 55 (enrollment 102 actual; start 2025-01-16; primary completion 2026-03-12; interventions include HRS-4729, HRS9531 and acetaminophen). A registration without results is not an outcome, and this record has no posted results.

Participants / model
Healthy participants aged 18 to 55
Treatment
HRS-4729 injection, subcutaneous, versus placebo
Follow-up
Start 16 January 2025; primary completion 12 March 2026
Study design
Trial registry record; no posted results
Funding
not stated in the source

The registry sponsor is Fujian Shengdi Pharmaceutical Co., Ltd., and the registry does not state that company's relation to Hengrui.

Read the original source
Company statement, 26 May 2026: phase 1 MAD topline, up to 16.0% at 12 weeks, not peer reviewed

Regulatory record

Kailera Therapeutics first-quarter 2026 results press release, 26 May 2026.

The company reported topline data from Hengrui's phase 1 SAD/MAD trial (NCT06762600). The MAD portion enrolled 60 participants (mean baseline weight 87.3 kg, BMI 31.4 kg/m2) who received once-weekly 1, 4, 8 or 12 mg HRS-4729, 4 mg ribupatide as active control, or placebo for 12 weeks. The release reports linear pharmacokinetics with a half-life of about 4 to 5 days, and at week 12 the 12 mg group achieved a mean weight loss of up to 16.0% from baseline versus 5.4% on placebo. Most treatment-emergent adverse events were mild to moderate and gastrointestinal, and liver fat fell in a dose-dependent way by MRI-PDFF.

Participants / model
Healthy participants in a 12-week multiple-ascending-dose cohort (60 participants; mean baseline weight 87.3 kg, BMI 31.4 kg/m2)
Treatment
HRS-4729 1, 4, 8 or 12 mg subcutaneously once weekly, 4 mg ribupatide as active control, or placebo
Follow-up
12 weeks
Study design
Company earnings release on a phase 1 multiple-ascending-dose cohort; not peer reviewed
Funding
not stated in the source

Not peer reviewed.

Read the original source
Company statement, 1 October 2026: 12 mg versus a dual-agonist control, 10 participants per arm

Regulatory record

Kailera Therapeutics press release, 1 October 2026, on GlobeNewswire.

In the MAD portion at week 12, the 12 mg group (N=10) achieved a mean weight loss of up to 16.0% and a 67.3% mean reduction in liver fat content, and the 4 mg ribupatide control group (N=10) had a mean body weight reduction of 16.7% and a 38.4% mean liver fat reduction. The GLP-1/GIP dual agonist control therefore lost numerically more weight (16.7%) than the tri-agonist's top dose (16.0%) in this trial; no statistical comparison between arms is reported and the two arms had 10 participants each. BMI ranged 28 to 40 kg/m2 in the MAD portion.

Participants / model
10 participants in each of the two arms named, in the MAD portion (BMI 28 to 40 kg/m2)
Treatment
HRS-4729 12 mg or ribupatide 4 mg subcutaneously once weekly
Follow-up
12 weeks
Study design
Company press release on a meeting presentation; not peer reviewed
Funding
not stated in the source

The 16.0% is described as up to 16.0% in the release, and each arm had 10 participants. The full phase 1 dataset and confidence intervals were not available, and the meeting abstract is cited only through this release.

Read the original source
Different molecule: retatrutide phase 3, 2339 adults, 80 weeks, -17.6% to -25.0%

Randomized controlled trial

Jastreboff AM et al. N Engl J Med. 2026. PMID 42814954.

Retatrutide is a triple agonist of the GIP, GLP-1 and glucagon receptors. In the phase 3 TRIUMPH-1 trial in 2339 adults with obesity without diabetes, mean body weight change at 80 weeks was -17.6% (4 mg), -23.7% (9 mg) and -25.0% (12 mg) versus -3.9% on placebo; the most common adverse events were gastrointestinal. This shows the receptor combination has phase 3 data for retatrutide. It is not evidence of the potency, efficacy or safety of KAI-4729, whose human data are limited to the company statements.

Participants / model
2339 adults with obesity without diabetes (retatrutide, not KAI-4729)
Treatment
Retatrutide 4, 9 or 12 mg subcutaneously once weekly, or placebo
Follow-up
80 weeks
Study design
Randomized phase 3 trial of a different molecule, used here as class context
Funding
not stated in the source

A different molecule. It is cited only to show the receptor combination has phase 3 data for retatrutide.

Read the original source
Different molecule: retatrutide phase 2, 338 adults, 48 weeks, heart rate and gastrointestinal events

Randomized controlled trial

Jastreboff AM et al. N Engl J Med. 2023;389(6):514-526. PMID 37366315.

In the retatrutide phase 2 trial in 338 adults with obesity, the gastrointestinal events were dose-related, and the abstract states that dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. A heart-rate effect is a class question for glucagon-receptor agonists; it was not reported for KAI-4729 in the sources reviewed.

Participants / model
338 adults with obesity (retatrutide, not KAI-4729)
Treatment
Retatrutide 1 to 12 mg subcutaneously once weekly
Follow-up
48 weeks
Study design
Randomized phase 2 trial of a different molecule, used here as class context
Funding
not stated in the source

A different molecule. Heart rate is a class question for glucagon-receptor agonists, not a finding for KAI-4729.

Read the original source
Registry: three phase 2 studies in China, none with results; Kailera plans a phase 1 outside China

Trial registry record

ClinicalTrials.gov records NCT07690826, NCT07660848 and NCT07843862, read on 10 October 2026; Kailera statements on a phase 1 trial outside China.

Phase 2 studies are registered and none has results. NCT07690826 (obesity, estimated n=252, not yet recruiting, registry start 2026-07, primary outcome percent change in body weight at week 32), NCT07660848 (MASH master protocol with HRS9531, estimated n=160, recruiting, start 2026-08-14) and NCT07843862 (type 2 diabetes versus mazdutide and placebo, estimated n=240, not yet recruiting, start 2026-10) are all sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. in China. These are registrations; none has results. Kailera says it plans a phase 1 trial outside China in 2026 with data expected in 2027.

Participants / model
Registered participants, not a clinical population
Treatment
HRS-4729 injection, once weekly
Follow-up
Registry start dates from July to October 2026
Study design
Trial registry records and a company statement; no results
Funding
not stated in the source

A registration describes a plan, not a result. Kailera's non-China phase 1 had no registry record on 10 October 2026.

Read the original source

Why is KAI-4729 in C tier?

C fits a compound whose only human data are company statements (26 May and 1 October 2026) from a 60-participant, 12-week study with 10 participants per top-dose arm, in which a GLP-1/GIP dual agonist control lost numerically more weight than the top tri-agonist dose. The shared receptor combination with retatrutide makes the biology plausible, but a mechanism match carries no efficacy or safety claim, so C rather than D.